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Background—A systematic assessment of potential disease-modifying compounds for
Parkinson's disease concluded that pioglitazone could hold promise for the treatment of patients
with this disease. We assessed the effect of pioglitazone on the progression of Parkinson's disease
in a multicentre, double-blind, placebo-controlled, futility clinical trial.

Author Manuscript

Methods—Participants with the diagnosis of early Parkinson's disease on a stable regimen of 1
mg/day rasagiline or 10 mg/day selegiline were randomly assigned (1:1:1) to 15 mg/day
pioglitazone, 45 mg/day pioglitazone, or placebo. Investigators were masked to the treatment
assignment. Only the statistical centre and the central pharmacy knew the treatment name
associated with the randomisation number. The primary outcome was the change in the total
Unified Parkinson's Disease Rating Scale (UPDRS) score between the baseline and 44 weeks,
analysed by intention to treat. The primary null hypothesis for each dose group was that the mean
change in UPDRS was 3 points less than the mean change in the placebo group. The alternative
hypothesis (of futility) was that pioglitazone is not meaningfully different from placebo. We
rejected the null if there was significant evidence of futility at the one-sided alpha level of 0.10.
The study is registered at ClinicalTrials.gov, number NCT01280123.

Author Manuscript

Findings—210 patients from 35 sites in the USA were enrolled between May 10, 2011, and July
31, 2013. The primary analysis included 72 patients in the 15 mg group, 67 in the 45 mg group,
and 71 in the placebo group. The mean total UPDRS change at 44 weeks was 4.42 (95% CI 2.55–
6.28) for 15 mg pioglitazone, 5.13 (95% CI 3.17–7.08) for 45 mg pioglitazone, and 6.25 (95% CI
4.35–8.15) for placebo (higher change scores are worse). The mean difference between the 15 mg
and placebo groups was −1.83 (80% CI −3.56 to −0.10) and the null hypothesis could not be
rejected (p=0.19). The mean difference between the 45 mg and placebo groups was −1.12 (80% CI
−2.93 to 0.69) and the null hypothesis was rejected in favour of futility (p=0.09). Planned
sensitivity analyses of the primary outcome, using last value carried forward (LVCF) to handle
missing data and using the completers' only sample, suggested that the 15 mg dose is also futile
(p=0.09 for LVCF, p=0.09 for completers) but failed to reject the null hypothesis for the 45 mg
dose (p=0.12 for LVCF, p=0.19 for completers). Six serious adverse events occurred in the 15 mg
group, nine in the 45 mg group, and three in the placebo group; none were thought to be definitely
or probably related to the study interventions.
Interpretation—These findings suggest that pioglitazone at the doses studied here is unlikely to
modify progression in early Parkinson's disease. Further study of pioglitazone in a larger trial in
patients with Parkinson's disease is not recommended.
Funding—National Institute of Neurological Disorders and Stroke.

Introduction
Author Manuscript

Parkinson's disease affects nearly 1% of the population aged over 60 years.1 Despite
effective therapies to treat symptoms of Parkinson's disease and many clinical trials,2,3 no
interventions have been proven to slow progression of disability (ie, achieve disease
modification). In 2001, the National Institute of Neurological Disorders and Stroke (NINDS)
created the Neuroprotection Exploratory Trials of Parkinson's Disease (NET-PD)
programme to assess therapies to slow progression of disability in Parkinson's disease (based
on recommendations by the Committee to Identify Neuroprotective Agents in Parkinson's
[CINAPS]).4 Pioglitazone was selected through a rigorous systematic review of agents to be
Lancet Neurol. Author manuscript; available in PMC 2016 August 01.
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tested by the NET-PD network as a potential disease-modifying agent in early Parkinson's
disease.4 Pioglitazone is approved by the US Food and Drug Administration (FDA) for the
treatment of type 2 diabetes and acts to reduce insulin resistance; it belongs to the class of
thiazolidinediones, the peroxisome proliferator-activated receptor γ (PPAR-γ) agonists.
Preclinical and early clinical evidence suggests that thiazolidinediones might have
neuroprotective effects in Parkinson's disease and other neurodegenerative diseases.5–9
Although the precise mechanisms through which PPAR-γ agonists might provide
neuroprotection are still unclear, they inhibit the activation of microglia and astrocytes and
production of pro-inflammatory cytokines and nitric oxide.10 PPAR-γ coactivator 1-α
(PGC-1α) is a transcriptional coactivator that controls mitochondrial biogenesis and
oxidative stress.11 Preclinical data in rodent and primate Parkinson's disease models showed
good CNS penetration of pioglitazone and neuroprotective effects at a dose in animals that is
the equivalent of the FDA-approved dose for use in human beings.11–14

Author Manuscript
Author Manuscript

Our primary objective was to assess the effect of pioglitazone on the progression of
Parkinson's disease to establish whether further study of this agent is futile. The study
known as FS-ZONE was based on the futility design (non-superiority) that has been used in
two phase 2 studies done by NET-PD.15,16 Futility studies are phase 2 clinical trials
designed to identify and eliminate compounds that have low likelihood of being efficacious
in definitive efficacy studies by comparing the primary outcome measure in the treatment
group versus placebo to a prespecified threshold value.17,18 Progression of Parkinson's
disease was measured by change in total Unified Parkinson Disease Rating Scale score
(UPDRS parts I–III)19 between the baseline and the 44 week visit. If both doses of
pioglitazone were non-futile, the plan was to select the dose that was associated with the
smallest (better) change of the UPDRS score. A final decision about whether to continue
studying that dose had also to take into account tolerability, toxicity, and other safety issues.

Methods
Study design and participants
The trial was a multicentre, three-group, double-blind, placebo-controlled parallel group
study. The trial was organised by the Clinical Trials Coordination Center (CTCC) at the
University of Rochester, NY, USA, the Statistical Center at the Division of Biostatistics,
University of Texas School of Public Health, TX, USA, and the NINDS.

Author Manuscript

Participants were men and women aged 30 years or older with idiopathic Parkinson's disease
based on UK Brain Bank diagnostic criteria20 diagnosed within 5 years of enrolment with a
Hoehn and Yahr score of 2 or less. Participants had to be on a stable dosage of rasagiline 1
mg/day or selegiline 10 mg/day for at least 8 weeks but not more than 8 months and were
expected to remain on that dose for the duration of the study. The rationale for enrolling
patients on monoamine oxidase type B inhibitor (MAO-BI) therapy was to reduce the
number of participants needing additional dopaminergic therapy during the study. Key
exclusion criteria (the full list is in the appendix) included exposure to other dopaminergic
Parkinson's disease therapy or amantadine within 60 days before baseline visit or for 90 days
or more at any point in the past. Patients with diabetes (glycated haemoglobin [HgbA1c]
≥6% at screening) were excluded. All participants signed a written informed consent before
Lancet Neurol. Author manuscript; available in PMC 2016 August 01.
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entry into the study. The study was done in accordance with the Good Clinical Practice
guidelines.
The steering committee developed the protocol and consent forms, and guided the
implementation of the trial. The protocol and consent forms were approved by a NINDSappointed oversight board, an independent data safety monitoring board (DSMB), and the
institutional review boards of each of the participating sites. The DSMB monitored the
safety, data integrity, and progress of the trial.
Randomisation and masking

Author Manuscript

Eligible patients with Parkinson's disease were randomly assigned (1:1:1) to one of three
study groups: 15 mg/day pioglitazone, 45 mg/day pioglitazone, or placebo. Dose selection
was based on the preclinical data showing a neuroprotective effect within 15–45 mg/kg
human dose equivalent11–14 and these doses falling within the FDA-approved range for use
in the human diabetic population. Participants and investigators were masked to treatment
group. The Statistical Coordination Center generated the random allocation sequence using a
permuted block randomisation scheme, and the sites accessed the masked treatment
assignment via a secure webpage.

Author Manuscript

Pioglitazone was purchased from the manufacturer (Takeda Pharmaceuticals America,
Deerfield, IL, USA). University of Iowa Pharmaceuticals over-encapsulated the active
tablets and created the placebo to match in accordance with current Good Manufacturing
Practice regulations. The University of Rochester Clinical Materials Services Unit provided
packaging, labelling, and distribution of the study drug in participant-specific kits. Active
study drug capsules contained 15 mg pioglitazone. Identical in appearance and taste, placebo
contained microcrystalline cellulose.
Procedures
At the screening visit, participants had a baseline medical history interview, physical and
neurological examination, electrocardiogram, UPDRS, and assessments of mood, cognition,
and disability. Blood and urine were obtained for clinical laboratory tests, a pregnancy test
for women of childbearing potential, and a test for HgbA1c. Blood and urine samples were
also collected from consenting participants for measurement of exploratory biomarkers.
After the baseline visit, participants were reassessed at 2 weeks (within 3 days) by telephone
and at 4, 16, 28, and 44 weeks (within 5 days) in person.

Author Manuscript

Study drug was given orally, three capsules once daily. Titration of pioglitazone to 45
mg/day target dose occurred in 15 mg increments, once every 2 weeks. Dose reduction for
intolerability was allowed at any point during the study and participants were maintained on
the highest tolerated dose up to their assigned dose.
Outcomes
The primary outcome was change in total UPDRS score between the baseline visit and 44
weeks. Data for participants needing additional symptomatic therapy before 44 weeks were
imputed for the primary analysis, but these participants continued to be followed for

Lancet Neurol. Author manuscript; available in PMC 2016 August 01.
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secondary analyses. Secondary outcome measures were the change in individual parts of the
UPDRS, change in ambulatory capacity,21 change in Schwab and England Activities of
Daily Living (SEADL) scale,22 change in Parkinson's Disease Questionnaire 39
(PDQ-39),23 change in Mattis Dementia Rating Scale (DRS),24 and change in the Geriatric
Depression Scale (GDS-15).25 Secondary measures of safety and tolerability were the
proportion of participants who completed the study on their assigned dose of study drug, the
adverse event frequency and severity, changes in vital signs, and clinical laboratory values.
Exploratory outcome measures included the effect of pioglitazone on blood and urine
biomarkers and the association of concentrations of these biomarkers with change in total
UPDRS score. Results of the biomarkers analyses will be reported separately. The
University of Pennsylvania Smell Identification Test (UPSIT) was included in the initial
protocol as an exploratory measure, but owing to budgetary constraints no UPSIT data were
collected at follow-up.

Author Manuscript

Statistical analysis
For each dose group, the primary null hypothesis was that pioglitazone reduces the mean
UPDRS decline over 44 weeks by 3 points or more compared with placebo. The alternative
hypothesis (of futility) was that pioglitazone is not meaningfully different from placebo. The
statistical hypotheses were H0: μ ≤ μp – 3 versus HA: μ > μp – 3, where μ was the expected
total UPDRS change score from baseline to 44 weeks for the active treatment group and μp
was the expected placebo total UPDRS change score. If the null hypothesis was rejected at a
significance level of 0.10, then the drug would be unlikely to be effective and not considered
for further investigation.

Author Manuscript

To estimate the sample size, we used the UPDRS change for patients treated with rasagiline
(1 mg daily) in the controlled trial of efficacy of rasagiline in early Parkinson's disease
(TEMPO).26 The approximate mean UPDRS change from 8 weeks to 52 weeks (ie, 44
weeks) was 4.5 (SD 8.0), which provided an estimate of μp and was the rationale for the 44
week duration of our study. Under the null hypothesis we assumed μ to be μp – 3, which is
1.5. Under these assumptions (H0: μ=1.5 and HA: μ=4.5), with 65 patients per group, a twosample t-test at 0.10 one-sided significance level had 80% power to reject the null
hypothesis and declare futility if a true difference existed. Assuming a dropout rate of 5%,
the sample size was inflated from 65 to 72 patients per treatment group.27

Author Manuscript

Under the intention-to-treat principle all randomly assigned patients were included in the
primary analyses. Patients who needed additional symptomatic therapy before 44 weeks
were considered missing primary outcome data. Missing 44 week UPDRS assessments were
imputed using multiple imputation28 by using all available data for each individual (before
the add-on of additional symptomatic therapy) and adjusting for the need for additional
symptomatic therapy (indicator variable), the length of time on rasagiline or selegiline at
baseline, and treatment group. The multiple imputation procedure assumed a monotone
missing mechanism, missing at random, and used 20 imputed datasets. The primary analysis
was adjusted for length of time on rasagiline or selegiline at baseline as a fixed effect and
enrolling site as a random effect in a mixed-effects linear model. Since this was a phase 2
study, the type I error rate was relaxed, and there was no correction for multiplicity for the

Lancet Neurol. Author manuscript; available in PMC 2016 August 01.
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two dose group comparisons. Planned secondary analyses of the primary outcome were last
value carried forward (LVCF), in which the last observation before additional symptomatic
therapy was carried forward to 44 weeks, and an analysis of completers, which included
participants who had a 44 week visit including ones who started additional symptomatic
therapy. As a post-hoc sensitivity analysis, a mixed-effects model was estimated that
included the repeated UPDRS measures available for all patients (assuming a first-order
autoregressive correlation structure for repeated measures) and was adjusted for baseline
UPDRS, clinical site (as a random effect), and time on rasagiline or selegiline at baseline.
For the secondary outcomes, the means and 95% CIs were reported by treatment group. A
non-parametric global statistical test was the prespecified analysis for the secondary
outcomes, to test whether each active treatment group had less progression compared with
placebo as measured by SEADL, PDQ-39, ambulatory capacity, and Mattis-DRS. Missing
data were imputed via multiple imputation. Patients were ranked on each outcome, and then
the ranks were summed. Higher ranks were worse. The study is registered at
ClinicalTrials.gov, number NCT01280123.

Author Manuscript

Role of the funding source
The study sponsor did not participate in the design of the study, but a representative of
NINDS (D Babcock, NINDS) participated in data interpretation and in the writing of the
report. NINDS approved the study protocol, had an oversight role in the data collection and
analysis, and reviewed and approved the decision to submit the paper for publication. All
authors had full access to all of the data in the study, and TS had responsibility for the final
decision to submit the report for publication.

Results
Author Manuscript

Between May 10, 2011, and July 31, 2013, 604 potential participants were identified from
pre-screening chart review. Of these, 208 were ineligible, 186 declined study participation,
and the remaining 210 eligible patients were randomly assigned to the three treatment
groups at 35 sites (figure 1). Baseline demographics and clinical characteristics were similar
across the three treatment groups except for a difference in GDS-15 (table 1).

Author Manuscript

The primary analysis suggested that the 45 mg treatment was futile: the mean difference
between the 45 mg and placebo groups was −1.12 (80% CI −2.93 to 0.69), and we rejected
the null hypothesis that the 45 mg group was 3 or more points better than the placebo group
(p=0.09). The primary analysis did not indicate futility for the 15 mg group: the mean
difference between the 15 mg and placebo groups was −1.83 (80% CI −3.56 to −0.10), and
the null hypothesis could not be rejected (p=0.19; table 2). Change in UPDRS from baseline
to week 44 for each treatment group is presented in figure 2. The planned sensitivity
analyses of the primary outcome suggested that the 15 mg treatment was futile in the last
value carried forward (p=0.09) and completers only (p=0.09) analyses, and this was
supported by the post-hoc repeated measures mixed model analyses (p=0.05). The planned
analyses indicated that the null hypothesis could not be rejected for the 45 mg group (p=0.12
for the last value carried forward, p=0.19 for the completers) but the post-hoc repeated
measures mixed model did not (p=0.04; table 2). For secondary efficacy outcomes, the mean

Lancet Neurol. Author manuscript; available in PMC 2016 August 01.
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changes from baseline to 44 weeks for the treatment groups were similar to placebo (table
3).
In the non-parametric global statistical test, to assess the change from baseline to 44 weeks
in SEADL, PDQ-39, ambulatory capacity, and Mattis-DRS, the mean (SD) summed rank
was 435 (137) for the 15 mg group, 427 (139) for the 45 mg group, and 404 (141) for the
placebo group (15 mg vs placebo, p=0.20; 45 mg vs placebo, p=0.37).

Author Manuscript

Of the 210 participants enrolled, 204 (97%) remained in the study for 44 weeks, and 195
(93%) remained active and on study drug. There were no deaths or treatment unmasking.
Overall, 30 (14%) participants needed additional symptomatic therapy before 44 weeks
(nine [13%] in the 15 mg group, 11 [16%] in the 45 mg group, and ten [14%] in the placebo
group). Missing data occurred owing to the need for additional symptomatic therapy,
withdrawal of consent, or loss to follow-up; these data were imputed for the total UPDRS at
44 weeks for 35 (17%) patients (ten in the 15 mg group, 14 in the 45 mg group, and 11 in
the placebo group). Tolerability, defined as the proportion of the participants taking the
assigned dose for 44 weeks, was slightly lower in the pioglitazone groups (62 of 72 in the 15
mg group [86%, 95% CI 78–94], 54 of 67 in the 45 mg group [81%, 71–90], and 67 of 71 in
the placebo group [94%, 89–100]).

Author Manuscript

18 patients had serious adverse events. Six occurred in the 15 mg group (ovarian cyst
ruptured, ankle fracture, atrial flutter, intestinal obstruction, and two cases of intervertebral
disc protrusion or degeneration). Nine occurred in the 45 mg group (one each of
spondylolisthesis, osteoarthritis requiring surgery, transient ischaemic attack, dehydration,
myocardial infarction, intestinal obstruction, and dyspnoea, hypoxia, and respiratory failure,
and two cases of confusion state). Three occurred in the placebo group (knee replacement,
atrial fibrillation and hypertension, and coronary artery stenosis). None of the serious
adverse events was judged as definitely or probably related to the study interventions by the
masked investigators. The frequency of non-serious adverse events was similar across
groups: 63 (88%) in the 15 mg group, 51 (76%) in the 45 mg group, and 59 (83%) in the
placebo group. Expected adverse events included the spectrum of adverse events in the
diabetic population, as summarised on the package insert. Table 4 shows the most frequently
occurring adverse events. Cardiovascular events occurred most frequently in the placebo
group (6% in 15 mg group, 9% in the 45 mg group, 11% in the placebo). Although a
difference in the proportion of oedema events was detected between all three groups
(Fisher's exact test, p=0.047), there was no significant pairwise difference versus placebo
(Fisher's exact test, 45 mg group vs placebo, p=0.35; 15 mg vs placebo, p=0.16). No other
statistically significant differences were noted.

Author Manuscript

Weight gain differed by treatment group: the 45 mg group had an adjusted mean increase of
1.6 kg (SD 2.15), compared with a decrease of −0.25 kg (2.13) for placebo and −0.02 kg
(2.13) for the 15 mg groups (all adjusted for time). Repeated measures analysis of weight
change over time indicated a significant difference between treatment groups (F2,207=14.9,
p<0.0001).

Lancet Neurol. Author manuscript; available in PMC 2016 August 01.
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Monitoring of depression was prespecified in the safety monitoring plan, although no
specific statistical criteria for stopping were established. Depression as measured by a
GDS-15 score of 5 or greater occurred more frequently at baseline in the placebo group (2
[3%] for 15 mg group, 1 [1%] for 45 mg group, and 10 [14%] for placebo), but the mean
GDS change at 44 weeks was similar by treatment group (table 3). Depressed mood adverse
events occurred similarly across treatment groups (2 [3%] for 15 mg group, 3 [5%] for 45
mg group, 3 [4%] for placebo). There were no significant differences in laboratory values by
treatment group over time or body-mass index (data not shown).

Discussion

Author Manuscript

Our results suggest that both doses of pioglitazone are unlikely to be effective as
interventions to slow progression of disability in early Parkinson's disease and we do not
recommend that they are considered for further study. Although 15 mg pioglitazone was not
futile in the primary analysis, absence of efficacy on all preplanned sensitivity analyses and
the secondary outcome measures suggest this dose is futile as well.
Pioglitazone was chosen by the CINAPS panel of experts for testing based on the results of
well conducted preclinical studies showing reproducible neuroprotective effects in tissue
culture and animal models.4,29,30 Unfortunately, this is another study in which animal
models were not predictive of efficacy in human beings. A possible explanation for negative
outcomes is that toxin animal models are not reflective of Parkinson's disease pathogenesis.
Another possibility is that pioglitazone failed to reach the target nigral neurons and achieve
sufficient drug exposure in this study, although good CNS penetration and target
engagement were shown in primate studies.13

Author Manuscript
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Alternatively, it is possible that the beneficial effect of pioglitazone was missed owing to
pitfalls of the study design, including the choice of the primary outcome measure. Although
whether UPDRS is the best outcome measure for the assessment of disease-modifying
benefit in early Parkinson's disease remains to be proven, it is the best validated measure and
the one that has extensive data showing its sensitivity to change in early Parkinson's
disease.31 Consistent findings for all secondary outcomes, which included a spectrum of
validated measures of quality of life, disability, and cognitive impairment, support an
absence of biological effect rather than a failure to capture and measure an effect. The
biomarkers also failed to show a separation of the active treatment groups from placebo and
as such are concordant with the conclusions drawn from the clinical study (these results will
be reported separately). If serum and urine biomarkers had shown a shift in the predicted
direction, then an argument could have been made for a biological effect that was not
captured by the clinical measures. The finding that both clinical and biological markers
failed to move is disappointing, but solidifies the conclusion that pioglitazone is not
promising for further testing in early Parkinson's disease.
Another consideration is the short duration of this and other Parkinson's disease futility
trials. 1 year or less amounts to a small proportion of the overall clinical course of
Parkinson's disease. The major objective of futility studies is to screen out quickly
compounds that do not work. Studies of such short duration might miss important disease-
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modifying effects that could be shown if patients were followed up for longer. Longer
studies impose a greater burden on patients and higher cost. Ideally, future phase 2 studies of
disease modification in Parkinson's disease will rely on biomarkers that will increase the
sensitivity of the analysis over shorter follow-up. Another important consideration for future
studies is how early Parkinson's disease is defined, as the onset of classic motor symptoms
might be late biologically. Neuroprotection might not be feasible unless we intervene at the
premotor stage of the disease. Of the other 12 agents recommended by CINAPS for clinical
testing, most have entered phase 2 studies and four have completed phase 3 studies.
Unfortunately, all studies have been negative so far.15,32,33

Author Manuscript
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A novel aspect of this study is that the participants were required to be treated with MAO-BI
therapy at the time of enrolment. The rationale for this inclusion criterion was to reduce the
number of patients who would need other dopaminergic treatment during the trial. Untreated
Parkinson's disease patients are often enrolled to assess short-term (1 year or less) effects of
a potential disease-modifying drug in exploratory trials. However, nearly half of the
participants might need dopaminergic therapy before the end of follow-up.34 This poses a
major problem for the primary analysis because these patients' outcomes have to be carried
forward from the last observed visit before initiation of dopaminergic therapy, or these data
must be imputed. Treatment of de novo Parkinson's disease participants with low-dose
MAO-BI therapy might delay the time to initiation of additional dopaminergic therapy by
providing symptomatic benefit that might be mild enough to allow for detection of
improvement due to a study intervention, should one exist. Indeed, only 30 (14%)
participants needed additional dopaminergic therapy in this study, which is a two-to-threefold reduction compared with the previously completed trials in similar populations.34
MAO-BIs are unlikely to have masked a beneficial effect of pioglitazone because each
treatment group in this study worsened similarly to those treated with 1 mg rasagiline in the
TEMPO study,26 which was used to estimate the placebo effect for the power calculations of
this trial. On the basis of these data we propose to consider enrolment of patients on a stable
regimen of a mild symptomatic therapy such as MAO-BIs in future phase 2 disease
modification trials.
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Our data show that pioglitazone is unlikely to be efficacious as a disease-modifying
intervention in early Parkinson's disease and therefore is not recommended for further
testing for that indication. Although our negative results are disappointing, the design of this
futility study is an example of a useful and efficient study design that can exclude a
compound unlikely to be successful in larger and more costly phase 3 studies.
Unfortunately, as was seen in the recent NET-PD study of creatine,35 even compounds
deemed non-futile in futility studies might also fail in longer studies. Accordingly, much
attention has shifted to discovery and validation of biomarkers of disease progression, which
we hope will accelerate the development of disease-modifying or curative agents.
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Research in context
Evidence before this study
We searched PubMed for articles published in English before Jan 15, 2015, using the
terms “Parkinson's disease”, “disease modification”, “clinical trials”, and “pioglitazone”.
As of that date, no agents had proven to be disease-modifying agents (ie, to slow
progression) in patients with Parkinson's disease and no studies had assessed the potential
disease-modifying effects of pioglitazone.
Added value of this study

Author Manuscript

This is the first randomised controlled trial of pioglitazone, a peroxisome proliferatoractivated receptor γ agonist, as a potential disease-modifying agent in patients with
Parkinson's disease. The rationale for the choice of study agent was based on the robust
preclinical data showing a neuroprotective effect in animal models at the doses approved
for use in human beings. Although the findings of this trial do not warrant further testing
of pioglitazone in patients with Parkinson's disease, the design of our study could guide
that of other studies, as we have shown that this design is useful and efficient to exclude a
compound unlikely to be successful in larger and more costly phase 3 trials.
Implications of all available evidence
These findings suggest that pioglitazone at the doses studied here is unlikely to modify
progression in early Parkinson's disease. Further study of pioglitazone in a larger trial in
Parkinson's disease is not recommended, although other peroxisome proliferatoractivated receptor γ agonists might deserve further exploration as disease-modifying
agents in Parkinson's disease.
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Figure 1. Trial profile
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Figure 2. Change in total Unified Parkinson's Disease Rating Scale (UPDRS) over time by
treatment group

Means (95% CI) are adjusted for site, time on rasagiline or selegiline at baseline, and
baseline UPDRS (from repeated measures mixed model). Assessments on participants
taking additional symptomatic therapy were excluded.
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Table 1

Baseline demographics and clinical characteristics
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15 mg pioglitazone (n=72)

45 mg pioglitazone (n=67)

Placebo (n=71)

Age (years)

61.3 (10.6)

58.8 (9.2)

59.0 (9.9)

Years of education

17.1 (3.1)

16.2 (3.3)

16.8 (3.0)

Males

53 (74%)

47 (70%)

48 (68%)

Non-latino whites

58 (81%)

63 (94%)

63 (89%)

Right-handed

62 (86%)

62 (93%)

62 (87%)

Duration of PD symptoms (years)

2.3 (1.9)

2.0 (1.2)

2.3 (2.3)

Time since PD diagnosis (years)

0.8 (07)

0.7 (0.7)

0.8 (0.7)

UPDRS total

23.8 (9.9)

21.2 (8.8)

21.7 (8.7)

UPDRS mental

0.8 (0.9)

0.8 (0.9)

0.9 (1.1)

UPDRS motor

17.1 (7.7)

15.0 (7.1)

15.3 (6.5)

UPDRS ADL

5.9 (3.2)

5.5 (2.9)

5.5 (3.0)

Ambulatory capacity

1.1 (0.9)

0.8 (0.8)

1.1 (0.9)

SEADL*

93.8 (4.9)

94.1 (5.0)

93.9 (5.0)

PDQ-39 Summary Index

8.5 (8.1)

8.1 (5.9)

10.6 (7.9)

GDS-15

1.4 (1.4)

1.1 (1.3)

1.8 (1.9)

138.6 (8.2)

138.8 (10.2)

138.0 (11.4)

4.1 (2.2)

4.0 (2.0)

3.7 (1.9)

Mattis-DRS*
Months on rasagiline or selegiline
GDS-15 ≥5

2 (2.8%)

1 (1.5%)

10 (14.1%)

Rasagiline use

60 (83.3%)

57 (85.1%)

60 (84.5%)

Selegiline use

12 (16.7%)

10 (14.9%)

11 (15.5%)

Author Manuscript

Data are mean (SD) or n (%). UPDRS=Unified Parkinson's Disease Rating Scale. ADL=activities of daily living. SEADL=Schwab and England
Activities of Daily Living scale. PDQ-39=Parkinson's Disease Questionnaire 39. GDS-15=15-item Geriatric Depression Scale. DRS=Dementia
Rating Scale.
*
Higher scores are associated with less severe clinical presentation; for all other clinical symptoms, higher scores are associated with more severe
presentation.
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Patients analysed* (n)

67
71

45 mg pioglitazone

Placebo

71

67

72

71

67

72

67
71

45 mg pioglitazone

Placebo

72
67
71

15 mg pioglitazone

45 mg pioglitazone

Placebo

Mixed model repeated measures¶

72

15 mg pioglitazone

60

53

62

70

63

71

5.39 (3.86–6.91)

4.42 (2.80–6.03)

4.25 (2.75–5.75)

4.47 (2.78–6.17)

2.79 (0.55–5.03)

3.35 (1.48–5.23)

0.04
‥

1.77
‥

0.05

‥

‥

1.69

0.19

0.89

1.35

0.09

‥

‥
§

0.12

0.09

‥

0.09

0.19

p value (one sided)

1.2

1.35

‥

1.34

0.88

H0:μ≤μi−3 t statistic†

Post-hoc sensitivity analysis (no imputation at 44 weeks; uses repeated measures for all 210 patients; patients without a 44 week assessment contributed to earlier timpoints only).

¶

Prespecified secondary analyses of the primary outcome.

§

Prespecified primary analysis.

‡

For each dose group, the primary null hypothesis was that pioglitazone reduces the mean Unified Parkinson's Disease Rating Scale (UPDRS) decline over 44 weeks by 3 points or more compared with
placebo; the alternative hypothesis (of futility) is that pioglitazone is not meaningfully different from placebo; except where indicated, the mean changes in UPDRS scores were adjusted for site (random
effect) and time on rasagiline or selegiline at baseline.

†

5.34 (3.79–6.88)

3.87 (2.08–5.65)

4.03 (2.14–5.92)

6.25 (4.35–8.15)

5.13 (3.17–7.08)

4.42 (2.55–6.28)

Mean (95% CI)

Completers only, actual value at 44 weeks (includes visits on additional dopaminergic therapy; unadjusted)

72

15 mg pioglitazone

Last value carried forward (unadjusted)§

71

67

45 mg pioglitazone

Placebo

72

15 mg pioglitazone

Intention-to-treat sample, multiple imputation‡

Patients enrolled (n)

Number of patients contributing a 44 week measure.

*
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Change in total Unified Parkinson's Disease Rating Scale from baseline to 44 weeks
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Table 3

Secondary outcomes: change from baseline to 44 weeks

Author Manuscript

15 mg pioglitazone (n=72)

45 mg pioglitazone (n=67)

Placebo (n=71)

UPDRS mental

0.10 (−0.16 to 0.36)

0.09 (−0.18 to 0.36)

0.18 (−0.13 to 0.49)

UPDRS motor

3.12 (1.79 to 4.46)

3.10 (1.29 to 4.90)

3.86 (2.47 to 5.26)

UPDRS ADL

1.44 (0.76 to 2.12)

1.44 (0.72 to 2.17)

1.73 (0.9 to 2.56)

Ambulatory capacity

0.39 (0.16 to 0.61)

0.38 (0.07 to 0.70)

0.40 (0.17 to 0.64)

−2.12 (−3.47 to −0.78)

−2.52 (−3.95 to −1.09)

−1.84 (−3.49 to −0.18)

2.03 (0.47 to 3.59)

2.08 (0.32 to 3.84)

0.08 (−1.59 to 1.76)

GDS-15

0.13 (−0.33 to 0.58)

0.38 (−0.10 to 0.85)

0.18 (−0.37 to 0.72)

Mattis-DRS*

1.16 (−1.26 to 3.58)

2.11 (−0.41 to 4.63)

3.16 (0.66 to 5.65)

SEADL*
PDQ-39 Summary Index

Author Manuscript

Data are mean (95% CI). Secondary outcomes analyses include all patients enrolled and are change from baseline to 44 weeks. Missing data
imputed with multiple imputation. Means are adjusted for site. UPDRS=Unified Parkinson's Disease Rating Scale. ADL=activities of daily living.
SEADL=Schwab and England Activities of Daily Living scale. PDQ-39=Parkinson's Disease Questionnaire 39. GDS=Geriatric Depression Scale.
DRS=Dementia Rating Scale.
*

Higher scores are associated with less severe clinical presentation; for all other clinical symptoms, higher scores are associated with more severe
presentation.
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Table 4

Frequently occurring adverse events

Author Manuscript

Placebo

15 mg pioglitazone

45 mg pioglitazone

Total

Oedema

9 (13%)

4 (6%)

13 (19%)

26 (12%)

Cardiovascular events

8 (11%)

4 (6%)

6 (9%)

18 (9%)

Diarrhoea

3 (4%)

7 (10%)

3 (4%)

13 (6%)

Nausea

3 (4%)

6 (8%)

7 (10%)

16 (8%)

11 (15%)

12 (17%)

7 (10%)

30 (14%)

Raised blood creatine phosphokinase
Dizziness

6 (8%)

5 (7%)

6 (9%)

17 (8%)

Fatigue

3 (4%)

8 (11%)

2 (3%)

13 (6%)

Data are n (%) of patients.
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